Pages that link to "Q84919012"

The following pages link to Bevacizumab in the treatment of ovarian cancer (Q84919012):

Displaying 20 items.

• Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial (Q33427744) (← links)
• Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells (Q33604480) (← links)
• What's fueling the biotech engine-2011 to 2012. (Q34316400) (← links)
• Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer (Q34833628) (← links)
• Bevacizumab plus ipilimumab in patients with metastatic melanoma (Q35012765) (← links)
• A view on dendritic cell immunotherapy in ovarian cancer: how far have we come? (Q35475233) (← links)
• Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer (Q35909674) (← links)
• Decreased serum level and increased urinary excretion of vascular endothelial growth factor-C in patients with chronic kidney disease (Q36465664) (← links)
• New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. (Q36889642) (← links)
• Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer (Q37220528) (← links)
• Ascites analysis by a microfluidic chip allows tumor-cell profiling (Q37409535) (← links)
• Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53 (Q37411955) (← links)
• Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth (Q37430771) (← links)
• Dendritic cell-based immunotherapy in ovarian cancer (Q37554417) (← links)
• Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer (Q38122265) (← links)
• Meta-analysis of the relation between vitamin D receptor gene BsmI polymorphism and susceptibility to ovarian cancer (Q39399685) (← links)
• VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients (Q42229919) (← links)
• Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). (Q46567658) (← links)
• Identifying prognostic signatures in the blood of ovarian cancer patients (Q57693926) (← links)
• Adipocytes: active facilitators in epithelial ovarian cancer progression? (Q99615840) (← links)